Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD70-targeted CAR-T in Advanced Solid Tumors
NCT06010875Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD70 CAR-T cells in renal cell carcinoma (RCC), ovarian cancer, Cervical Cancer (CC) and 1 more (2 arms), sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Adverse events after CD70 CAR-T cells infusion at 28 days and Maximum tolerated dose of CD70 CAR-T cells at 28 days. Started Nov 2023; status: recruiting.
02
Drugs
CD70 CAR-T cells
03
Conditions
renal cell carcinoma (RCC)ovarian cancerCervical Cancer (CC)solid tumor
Beyond the preview
Go deeper on NCT06010875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010875.